Entrapment of haemoglobin into liposomes by the dehydration-rehydration method: vesicle characterization and in vivo behaviour.
Haemoglobin (Hb) was isolated from human erythrocytes under conditions which maintained NADH-cytochrome-b5 reductase activity and suppressed oxidation of Hb during storage at 4 degrees C (methaemoglobin values < 3% after 29 days). Hb was entrapped into liposomes composed of hydrogenated egg phosphatidylcholine and equimolar cholesterol according to the dehydration/rehydration procedure of Kirby and Gregoriadis ((1984) Biotechnology 2, 979). However, encapsulation of Hb in its intact form was poor (< 5%) as a result of its oxidation and denaturation during freeze-drying. The addition of cryoprotectants and the use of both, higher initial concentrations of Hb and very small void vesicles resulted in Hb-rich dehydration/rehydration vesicles (phospholipid/Hb molar ratio of about 200:1) of the preferred size of 110 nm (mean). Highly homogeneous and small void vesicles as starting material were prepared using the one-step method of Brandl et al. ((1990) Drug Dev. Ind. Pharm. 16, 2167). The cryoprotectants were chosen with respect to their sufficient protection of Hb without affecting its loading into vesicles during freeze-drying and rehydration. 51Cr-labelling of Hb was used for the in vivo monitoring of the fate of Hb-containing vesicles rather than 125I-labelling since the latter induced strong interactions of Hb with liposomes. Upon intravenous administration into rats, liposomal 51Cr-Hb showed greater blood levels and prolonged circulation times in the blood compared to free Hb. The present approach provides high yield entrapment of labile molecules into vesicles of small size known to exhibit long circulation time.
Brandl
M
M
Centre for Drug Delivery Research, School of Pharmacy, London, UK.
Gregoriadis
G
G
D000818:Animals; D004337:Drug Carriers; D004355:Drug Stability; D005260:Female; D006454:Hemoglobins / Q000008:administration & dosage* / Q000737:chemistry; D008081:Liposomes / Q000737:chemistry* / Q000493:pharmacokinetics; D008297:Male; D010084:Oxidation-Reduction; D010715:Phosphatidylglycerols; D051381:Rats; D017208:Rats, Wistar; D012996:Solutions; D013696:Temperature
D004337:Drug Carriers; D006454:Hemoglobins; D008081:Liposomes; D010715:Phosphatidylglycerols; D012996:Solutions; C030345:1,2-dipalmitoylphosphatidylglycerol